科兴制药启动合作研发KXBS001生物类似药

Core Viewpoint - The strategic partnership between Kexing Pharmaceutical and Auscan Biopharmaceuticals marks Kexing's entry into the European and American biosimilar drug markets, highlighting the potential for growth in this sector due to a significant supply-demand gap in the EU market [1][2] Group 1: Strategic Partnership - Kexing Pharmaceutical has announced a strategic collaboration with Auscan Biopharmaceuticals to co-develop the biosimilar drug KXBS001, with a signing ceremony held in Shenzhen [1] - The partnership aims to leverage Auscan's expertise in large molecule fields such as monoclonal antibodies and ADCs, focusing on developing high-quality biosimilars that meet regulatory standards in China, the US, and Europe [2] Group 2: Market Potential - According to an IQVIA report, the EU currently holds about 40% of the global biosimilar market value, with 71% of patented biological drugs set to expire between 2024 and 2030 lacking corresponding biosimilar candidates in the pipeline, indicating substantial market potential for biosimilars in the EU [1] - Kexing's strategy emphasizes "innovation + internationalization," with a focus on antibody technology platforms and a comprehensive pipeline that includes monoclonal, bispecific, and multi-target antibody fusion proteins [1] Group 3: Future Outlook - Kexing Pharmaceutical aims to achieve a "curve overtaking" in the global market by leveraging its proactive international expansion and precise positioning in the European and American markets, which is expected to lay a solid foundation for future global competition [2]